UBS Group Portfolio holdings
UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UBS Group
UBS
|
+$1.48B |
| 2 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$690M |
| 3 |
VanEck Junior Gold Miners ETF
GDXJ
|
+$588M |
| 4 |
Truist Financial
TFC
|
+$532M |
| 5 |
VanEck Gold Miners ETF
GDX
|
+$278M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.3B |
| 2 |
Alibaba
BABA
|
+$771M |
| 3 |
AABA
Altaba Inc
AABA
|
+$759M |
| 4 |
STI
SunTrust Banks, Inc.
STI
|
+$503M |
| 5 |
BPL
Buckeye Partners, L.P.
BPL
|
+$467M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 49.31% |
| 2 | Technology | 9.89% |
| 3 | Financials | 7.42% |
| 4 | Healthcare | 6.84% |
| 5 | Consumer Discretionary | 5.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3901
Invesco S&P 500 Equal Weight Consumer Discretionary ETF
RSPD
$406M
| $1.4M | ﹤0.01% |
37,686
+105
| +0.3% | +$3.75K |
|
3902
CTS Corp
CTS
$1.7B
| $1.4M | ﹤0.01% |
46,490
+18,025
| +63% | +$522K |
|
|
MNTA
3903
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $1.39M | ﹤0.01% |
70,639
-46,775
| -40% | -$748K |
|
3904
State Street SPDR S&P Oil & Gas Equipment & Services ETF
XES
$373M
| $1.39M | ﹤0.01% |
17,193
+4,862
| +39% | +$347K |
|
3905
OFG Bancorp
OFG
$2.2B
| $1.39M | ﹤0.01% |
58,768
+6,166
| +12% | +$135K |
|
3906
CALL
Abercrombie & Fitch
ANF
$5.76B
| $1.38M | ﹤0.01% |
+80,000
| New | +$1.32M |
|
3907
CALL
Cadence Design Systems
CDNS
$89.8B
| $1.38M | ﹤0.01% |
+19,900
| New | +$1.33M |
|
3908
Utah Medical Products
UTMD
$235M
| $1.38M | ﹤0.01% |
12,778
+1,812
| +17% | +$184K |
|
3909
Clearway Energy Class C
CWEN
$6.11B
| $1.38M | ﹤0.01% |
69,015
+6,738
| +11% | +$130K |
|
3910
CALL
Hilton Grand Vacations
HGV
$2.78B
| $1.38M | ﹤0.01% |
40,000
| – | – |
|
3911
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
$125M
| $1.38M | ﹤0.01% |
1,422
+1,320
| +1,294% | +$1.6M |
|
3912
Sunrun
RUN
$1.95B
| $1.38M | ﹤0.01% |
99,534
-15,056
| -13% | -$224K |
|
3913
Standex International
SXI
$3.44B
| $1.37M | ﹤0.01% |
17,312
+6,924
| +67% | +$526K |
|
3914
Fomento Económico Mexicano
FMX
$40.8B
| $1.37M | ﹤0.01% |
14,523
-2,800
| -16% | -$257K |
|
3915
Fresenius Medical Care
FMS
$12.1B
| $1.37M | ﹤0.01% |
37,243
+14,358
| +63% | +$509K |
|
3916
Shutterstock
SSTK
$154M
| $1.37M | ﹤0.01% |
32,011
+28,693
| +865% | +$1.15M |
|
3917
Patterson-UTI
PTEN
$4.16B
| $1.37M | ﹤0.01% |
130,469
-302,973
| -70% | -$2.74M |
|
3918
CALL
Range Resources
RRC
$9.02B
| $1.37M | ﹤0.01% |
282,500
-4,300
| -1% | -$17.3K |
|
3919
OneSpan
OSPN
$656M
| $1.37M | ﹤0.01% |
79,913
+25,805
| +48% | +$439K |
|
3920
Zymeworks
ZYME
$1.9B
| $1.37M | ﹤0.01% |
30,039
-12,328
| -29% | -$448K |
|
3921
John Hancock Multifactor Developed International ETF
JHMD
$964M
| $1.36M | ﹤0.01% |
46,098
-6,402
| -12% | -$185K |
|
3922
Invesco S&P Emerging Markets Low Volatility ETF
EELV
$421M
| $1.36M | ﹤0.01% |
56,730
-1,237
| -2% | -$28.8K |
|
3923
Northern Trust Global Quality Real Estate ETF
GQRE
$439M
| $1.36M | ﹤0.01% |
21,011
-175
| -0.8% | -$11.5K |
|
|
BTAI
3924
DELISTED
BioXcel Therapeutics
BTAI
| $1.36M | ﹤0.01% |
5,818
+824
| +16% | +$82.8K |
|
3925
Ligand Pharmaceuticals
LGND
$6.01B
| $1.36M | ﹤0.01% |
20,903
-59,170
| -74% | -$3.95M |
|
Similar funds
UBS Group's Q4 2019 Portfolio in Review
As of Q4 2019, UBS Group held 8,864 positions worth $287B, up 11% from $260B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
UBS Group's Q4 2019 filing shows 807 new, 4,306 increased, 2,683 reduced and 688 closed positions. Its largest new stake was Bristol-Myers Squibb Company Contingent Value Rights: 5,302,748 shares worth $16M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $1.3B.
By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, down from 50% a quarter earlier, followed by Technology and Financials.
- UBS Group's largest Q4 2019 buy was Bristol-Myers Squibb Company Contingent Value Rights: 5,302,748 shares worth $16M.
- UBS Group added most to UBS Group in Q4 2019, an estimated $1.48B increase.
- UBS Group's biggest Q4 2019 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.3B.
- UBS Group fully exited Altaba Inc in Q4 2019, selling an estimated $759M.
- UBS Group's ten largest holdings make up 13% of its $287B portfolio in Q4 2019.
- UBS Group opened 807 new positions and closed 688 in Q4 2019.
- UBS Group's portfolio value rose 11% quarter-over-quarter to $287B.
Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.